top of page
  • Recruiting

NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)

Updated: Feb 21

  • The ADVANCE trial

  • Dara-KRd

  • KRd

  • VRd


ADVANCE MYELOMA TRIAL dara-krd UNIVERSITY MIAMI

NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma (ADVANCE)


This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the standard of care treatment, which is lenalidomide, bortezomib, and dexamethasone (VRD).


Sponsor


Collaborator


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT04268498

Official Title: Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

First Posted: February 13, 2020

Click here for details on ClinicalTrials.gov

 


 

Drug: Bortezomib (Velcade)

Drug: Dexamethasone (Decadron)

Drug: Lenalidomide (Revlimid)

Drug: Acetaminophen

Drug: Diphenhydramine

Drug: Montelukast

Drug: Carfilzomib (Kyprolis)

Drug: Daratumumab (Darzalex)

Biological: Autologous Stem Cell Transplant (ASCT)

 
 

- Florida: Sylvester Comprehensive Cancer Center - University of Miami

- Florida: Moffitt Cancer Center Tampa

- Illinois: Rush University Medical Center Chicago

- New York: Roswell Park Cancer Institute Buffalo

- New York: Memorial Sloan-Kettering Cancer Center New York

- Texas: The University of Texas MD Anderson Cancer Center Houston

 

Locations

United States, Florida

United States, Illinois

United States, New York

United States, Texas

United States, Utah

Sweden

 

RELATED POSTS


NCT03710603: Phase 3 (Perseus) EMN17 - Dara-VRd Vs VRd - Daratumumab, VELCADE, Len, Dex VS VELCADE, Len, Dex in NDMM


NCT03652064: Phase 3 (CEPHEUS) MMY3019 - Dara-VRd Vs VRd - Bortezomib, Lenalidomide, Dex and +/- Daratumumab - NDMM


NCT04566328: Phase 3 (EQUATE) - EAA181 - Dara-VRd Vs Dara-Rd - Testing the Use of Combination Therapy in NDMM


NCT02195479: Phase 3 (ALCYONE) Dara-VMP Vs VMP - Bortezomib, Melphalan, Prednisone & Daratumumab


NCT02541383: Phase 3 (CASSIOPEIA) Dara-VTd Vs VTd - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT


NCT02874742: Phase 2 (GRIFFIN) - Dara-VRd Vs VRd - Daratumumab, Len., Bortezomib & Dex in NDMM


NCT03290950: Phase 2 (Manhattan) Dara-KRd - A Study of Daratumumab in Patients With NDMM wKRd-D


NCT02252172: Phase 3 (MAIA) Dara-Rd Vs Rd - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma


NCT03729804: Phase 3 (COBRA) - KRd Vs VRd in Patients with Newly Diagnosed Multiple Myeloma


NCT04096066: Phase 3 KRd Vs Rd - A Trial That Compare Two Treatments TIE - NDMM


NCT01402284: Phase 2 - KRd - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

 

NCT04483739: Phase 3 (Iskia) - Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Eligible for ASCT


NCT03319667: Phase 3 (IMROZ) - Isa-VRd Vs VRd - Isatuximab, Bortezomib, Lenalidomide and Dex NDMM


NCT04751877: Phase 3 (IFM2020-05) - Isa-VRd Vs Isa-Rd - Non-Frail NTE Myeloma Elderly Patients

 

NCT04923893: Phase 3 (CARTITUDE-5) VRd --> Cilta-cel Vs VRd --> Rd - NDMM- (No ASCT planned)


NCT05257083: Phase 3 (CARTITUDE-6) DVRd -> Ciltacabtagene Autoleucel Vs DVRd -> Transplant ASCT- NDMM

 

NCT01850524: Phase 3 (TOURMALINE-MM2) Ixa-Rd Vs Rd - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM




Comments


Commenting has been turned off.
Posts Archive
bottom of page